Atrium Therapeutics, Inc. Common Stock (RNA) SEC filings

Atrium Therapeutics, Inc. Common Stock (RNA) SEC filings — 10-K, 10-Q, 8-K, and Form 4 as cached from EDGAR. When an exhibit lands, this page shows the headline, the numbers, and why it matters.

Those exhibit numbers sit next to the income-statement cache: Latest reported RNA revenue for 2025-12-31 was $18.8M. Net income was -$684.6M. Revenue was up 72.1% from 2024-12-31 to 2025-12-31. RNA currently screens at market cap $217.5M. The RNA filings page is the source view; the stock page is the research view.

EDGAR remains the official archive. Lician caches 8-K exhibits so you can read what Atrium Therapeutics, Inc. Common Stock said without waiting on a live EDGAR scrape. Item 2.02 is the earnings exhibit — this page prefers EX-99.1 revenue, growth, EPS, and guidance over a form-type label. Form 4 insider prints stay on the same ticker timeline.